

**Listing of Amended Claims:**

1-36. (Canceled)

37. (Previously presented) An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:107.

38. (Previously amended) A fusion protein comprising a first polypeptide comprising the amino acid sequence of SEQ ID NO:107 and a second polypeptide.

39. (Currently amended) A ~~pharmaceutical~~ composition comprising a polypeptide of claim 37 and a physiologically acceptable carrier.

40. (Original) The composition of claim 39, further comprising a non-specific immune response enhancer.

41. (Original) The composition of claim 40, wherein the non-specific immune response enhancer is an adjuvant.

42-55. (Canceled)

56. (Previously presented) An isolated polypeptide comprising an immunogenic fragment of SEQ ID NO:107, wherein the immunogenic fragment of SEQ ID NO:107 is at least 9 amino acids in length.

57. (Previously presented) A fusion protein comprising a first polypeptide comprising an immunogenic fragment of SEQ ID NO:107, wherein the immunogenic fragment of SEQ ID NO:107 is at least 9 amino acids in length and a second polypeptide.

58. (Currently amended) A ~~pharmaceutical~~ composition comprising a polypeptide of claim 56 and a physiologically acceptable carrier.

59. (Previously presented) The composition of claim 58, further comprising a non-specific immune response enhancer.

60. (Previously presented) The composition of claim 59, wherein the non-specific immune response enhancer is an adjuvant.

61. (Previously presented) A fusion protein according to claim 38, where said second polypeptide is an *M. tuberculosis* antigen.

62. (Currently amended) A ~~pharmaceutical~~ composition comprising a fusion protein of claim 38 and a physiologically acceptable carrier.

63. (Currently amended) The ~~pharmaceutical~~ composition of claim 62, further comprising a non-specific immune response enhancer.

64. (Currently amended) The ~~pharmaceutical~~ composition of claim 63, wherein the non-specific immune response enhancer is an adjuvant.

65. (Previously presented) A fusion protein according to claim 57, where said second polypeptide is an *M. tuberculosis* antigen.

66. (Currently amended) A ~~pharmaceutical~~ composition comprising a fusion protein of claim 57 and a physiologically acceptable carrier.

67. (Currently amended) The ~~pharmaceutical~~ composition of claim 66, further comprising a non-specific immune response enhancer.

68. (Previously presented) The composition of claim 67, wherein the non-specific immune response enhancer is an adjuvant.

69. (Previously presented) An isolated polypeptide consisting of the amino acid sequence of SEQ ID NO:107.

70. (Previously presented) A fusion protein comprising a first polypeptide consisting of the amino acid sequence of SEQ ID NO:107 and a second polypeptide.

71. (Previously presented) A fusion protein according to claim 70, where said second polypeptide is an *M. tuberculosis* antigen.

72. (Currently amended) A ~~pharmaceutical~~ composition comprising a polypeptide of claim 69 and a physiologically acceptable carrier.

73. (Currently amended) A ~~pharmaceutical~~ composition comprising a fusion protein of claim 70 and a physiologically acceptable carrier.

74. (Currently amended) The ~~pharmaceutical~~ composition of claim 72, further comprising a non-specific immune response enhancer.

75. (Currently amended) The ~~pharmaceutical~~ composition of claim 74, wherein the non-specific immune response enhancer is an adjuvant.

76. (Currently amended) The ~~pharmaceutical~~ composition of claim 73, further comprising a non-specific immune response enhancer.

77. (Currently amended) The ~~pharmaceutical~~ composition of claim 76, wherein the non-specific immune response enhancer is an adjuvant.

78. (Previously presented) An isolated polypeptide consisting of an immunogenic fragment of SEQ ID NO:107, wherein the immunogenic fragment of SEQ ID NO:107 is at least 9 amino acids in length.

79. (Previously presented) A fusion protein comprising a first polypeptide consisting of an immunogenic fragment of SEQ ID NO:107, wherein the immunogenic fragment of SEQ ID NO:107 is at least 9 amino acids in length, and a second polypeptide.

80. (Previously presented) A fusion protein according to claim 79, where said second polypeptide is an *M. tuberculosis* antigen.

81. (Currently amended) A ~~pharmaceutical~~ composition comprising a polypeptide of claim 78 and a physiologically acceptable carrier.

82. (Currently amended) A ~~pharmaceutical~~ composition comprising a fusion protein of claim 79 and a physiologically acceptable carrier.

83. (Currently amended) The ~~pharmaceutical~~ composition of claim 81, further comprising a non-specific immune response enhancer.

84. (Currently amended) The ~~pharmaceutical~~ composition of claim 83, wherein the non-specific immune response enhancer is an adjuvant.

85. (Currently amended) The ~~pharmaceutical~~ composition of claim 82, further comprising a non-specific immune response enhancer.

86. (Currently amended) The ~~pharmaceutical~~ composition of claim 85, wherein the non-specific immune response enhancer is an adjuvant.